The First Department of Medicine, Wakayama Medical University, Wakayama, Japan.
Department of Diabetes, Endocrinology, and Metabolism, Japanese Red Cross Wakayama Medical Center, Wakayama, Japan.
Front Endocrinol (Lausanne). 2021 Jun 24;12:708333. doi: 10.3389/fendo.2021.708333. eCollection 2021.
SARS-CoV-2 infection (COVID-19) is currently a tremendous global health problem. COVID-19 causes considerable damage to a wide range of vital organs most prominently the respiratory system. Recently, clinical evidence for thyroidal insults during and after COVID-19 has been accumulated. As of today, almost all non-neoplastic thyroid diseases, i.e., Graves' disease, Hashimoto's thyroiditis, subacute, painless and postpartum thyroiditis, have been reported as a complication of COVID-19, and causality by the virus has been strongly implicated in all of them. Similar thyroid problems have been reported in the past with the SARS-CoV outbreak in 2002. In this review, we briefly look back at the reported evidence of alteration in thyroid functionality and thyroid diseases associated with SARS-CoV and then proceed to examine the issue with COVID-19 in detail, which is then followed by an in-depth discussion regarding a pathogenetic link between Coronavirus infection and thyroid disease.
SARS-CoV-2 感染(COVID-19)目前是一个巨大的全球健康问题。COVID-19 对广泛的重要器官造成了相当大的损害,最突出的是呼吸系统。最近,COVID-19 期间和之后甲状腺损伤的临床证据已经积累。截至今天,几乎所有的非肿瘤性甲状腺疾病,即格雷夫斯病、桥本甲状腺炎、亚急性、无痛性和产后甲状腺炎,都被报道为 COVID-19 的并发症,而且病毒的因果关系在所有这些疾病中都被强烈暗示。过去在 2002 年 SARS-CoV 爆发时也有类似的甲状腺问题报道。在这篇综述中,我们简要回顾了与 SARS-CoV 相关的甲状腺功能改变和甲状腺疾病的报道证据,然后详细研究了 COVID-19 的问题,随后深入讨论了冠状病毒感染和甲状腺疾病之间的发病机制联系。